JP2012530703A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012530703A5 JP2012530703A5 JP2012516072A JP2012516072A JP2012530703A5 JP 2012530703 A5 JP2012530703 A5 JP 2012530703A5 JP 2012516072 A JP2012516072 A JP 2012516072A JP 2012516072 A JP2012516072 A JP 2012516072A JP 2012530703 A5 JP2012530703 A5 JP 2012530703A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- substituted
- nhc
- present
- membered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 369
- 150000001875 compounds Chemical class 0.000 claims description 162
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 138
- 229910052757 nitrogen Inorganic materials 0.000 claims description 130
- 125000001931 aliphatic group Chemical group 0.000 claims description 115
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 114
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 114
- 125000005842 heteroatom Chemical group 0.000 claims description 114
- 229910052760 oxygen Inorganic materials 0.000 claims description 114
- 239000001301 oxygen Chemical group 0.000 claims description 114
- 229910052717 sulfur Chemical group 0.000 claims description 114
- 239000011593 sulfur Chemical group 0.000 claims description 114
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 94
- -1 —O—C 1-3 haloalkyl Chemical group 0.000 claims description 90
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 80
- 125000001153 fluoro group Chemical group F* 0.000 claims description 74
- 125000002723 alicyclic group Chemical group 0.000 claims description 68
- 229910052739 hydrogen Inorganic materials 0.000 claims description 61
- 239000001257 hydrogen Substances 0.000 claims description 61
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 55
- 125000000623 heterocyclic group Chemical group 0.000 claims description 51
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 42
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 40
- 150000003839 salts Chemical class 0.000 claims description 35
- 150000002431 hydrogen Chemical group 0.000 claims description 33
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 32
- 125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 claims description 26
- 125000003709 fluoroalkyl group Chemical group 0.000 claims description 26
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 20
- 125000005843 halogen group Chemical group 0.000 claims description 20
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 20
- 230000002062 proliferating effect Effects 0.000 claims description 20
- 125000002947 alkylene group Chemical group 0.000 claims description 18
- 229910052799 carbon Inorganic materials 0.000 claims description 18
- 150000001721 carbon Chemical group 0.000 claims description 18
- 229910052736 halogen Inorganic materials 0.000 claims description 16
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 14
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims description 12
- 150000002367 halogens Chemical class 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 10
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 10
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 10
- 208000034578 Multiple myelomas Diseases 0.000 claims description 10
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 10
- 206010033128 Ovarian cancer Diseases 0.000 claims description 10
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 10
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 10
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 10
- 206010006187 Breast cancer Diseases 0.000 claims description 8
- 208000026310 Breast neoplasm Diseases 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 8
- 201000005202 lung cancer Diseases 0.000 claims description 8
- 208000020816 lung neoplasm Diseases 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 102100022537 Histone deacetylase 6 Human genes 0.000 claims description 4
- 101000899330 Homo sapiens Histone deacetylase 6 Proteins 0.000 claims description 4
- WWGBHDIHIVGYLZ-UHFFFAOYSA-N N-[4-[3-[[[7-(hydroxyamino)-7-oxoheptyl]amino]-oxomethyl]-5-isoxazolyl]phenyl]carbamic acid tert-butyl ester Chemical compound C1=CC(NC(=O)OC(C)(C)C)=CC=C1C1=CC(C(=O)NCCCCCCC(=O)NO)=NO1 WWGBHDIHIVGYLZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 claims description 4
- 125000005308 thiazepinyl group Chemical group S1N=C(C=CC=C1)* 0.000 claims description 3
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims description 2
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims description 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims description 2
- 125000005874 benzothiadiazolyl group Chemical group 0.000 claims description 2
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 claims description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 claims description 2
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000004856 decahydroquinolinyl group Chemical group N1(CCCC2CCCCC12)* 0.000 claims description 2
- 125000002576 diazepinyl group Chemical group N1N=C(C=CC=C1)* 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 2
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 claims description 2
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims description 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 2
- 125000001425 triazolyl group Chemical group 0.000 claims description 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 4
- 125000004122 cyclic group Chemical group 0.000 claims 3
- 210000000481 breast Anatomy 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 0 CC(C(NO)=O)=CC(CCN(*)C1)=C1C=C Chemical compound CC(C(NO)=O)=CC(CCN(*)C1)=C1C=C 0.000 description 5
- 238000000034 method Methods 0.000 description 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21909609P | 2009-06-22 | 2009-06-22 | |
| US61/219,096 | 2009-06-22 | ||
| PCT/US2010/001801 WO2010151318A1 (en) | 2009-06-22 | 2010-06-21 | Substituted hydroxamic acids and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015012045A Division JP2015078237A (ja) | 2009-06-22 | 2015-01-26 | 置換ヒドロキサム酸およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012530703A JP2012530703A (ja) | 2012-12-06 |
| JP2012530703A5 true JP2012530703A5 (enExample) | 2013-08-08 |
| JP5798115B2 JP5798115B2 (ja) | 2015-10-21 |
Family
ID=43386815
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012516072A Expired - Fee Related JP5798115B2 (ja) | 2009-06-22 | 2010-06-21 | 置換ヒドロキサム酸およびその使用 |
| JP2015012045A Pending JP2015078237A (ja) | 2009-06-22 | 2015-01-26 | 置換ヒドロキサム酸およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015012045A Pending JP2015078237A (ja) | 2009-06-22 | 2015-01-26 | 置換ヒドロキサム酸およびその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US9096518B2 (enExample) |
| EP (1) | EP2445340B1 (enExample) |
| JP (2) | JP5798115B2 (enExample) |
| CA (1) | CA2765678A1 (enExample) |
| WO (1) | WO2010151318A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050089559A1 (en) * | 2003-10-23 | 2005-04-28 | Istvan Szelenyi | Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains |
| US8722929B2 (en) * | 2006-10-10 | 2014-05-13 | Valeant Pharmaceuticals International | N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators |
| US8367684B2 (en) * | 2007-06-13 | 2013-02-05 | Valeant Pharmaceuticals International | Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators |
| US8563566B2 (en) * | 2007-08-01 | 2013-10-22 | Valeant Pharmaceuticals International | Naphthyridine derivatives as potassium channel modulators |
| US7786146B2 (en) * | 2007-08-13 | 2010-08-31 | Valeant Pharmaceuticals International | Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators |
| US8624040B2 (en) | 2009-06-22 | 2014-01-07 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
| EP2445340B1 (en) | 2009-06-22 | 2016-05-18 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
| US8546588B2 (en) | 2010-02-26 | 2013-10-01 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
| WO2011106632A1 (en) * | 2010-02-26 | 2011-09-01 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
| WO2011130163A1 (en) | 2010-04-12 | 2011-10-20 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
| US8513421B2 (en) | 2010-05-19 | 2013-08-20 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
| WO2012027564A1 (en) | 2010-08-26 | 2012-03-01 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
| BR112013005609A2 (pt) | 2010-09-09 | 2019-09-24 | Hoffmann La Roche | composto de fórmula (i), composição, uso de um composto e novos compostos, processos, método e usos |
| US8765773B2 (en) | 2010-10-18 | 2014-07-01 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
| US8778931B2 (en) | 2010-12-22 | 2014-07-15 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
| WO2012117421A1 (en) | 2011-03-02 | 2012-09-07 | Orchid Research Laboratories Ltd | Histone deacetylase inhibitors |
| WO2013041407A1 (en) * | 2011-09-19 | 2013-03-28 | Cellzome Ag | Hydroxamic acids as hdac6 inhibitors |
| MA40532A (fr) | 2014-08-28 | 2021-04-28 | Asceneuron Sa | Inhibiteurs de glycosidases |
| US10183934B2 (en) | 2015-02-02 | 2019-01-22 | Forma Therapeutics, Inc. | Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors |
| SG11201708622UA (en) | 2015-02-02 | 2017-11-29 | Forma Therapeutics Inc | 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors |
| MX381953B (es) | 2016-02-25 | 2025-03-13 | Asceneuron S A | Sales de derivados de piperazina obtenidas por adicion de acidos. |
| US11612599B2 (en) | 2016-02-25 | 2023-03-28 | Asceneuron Sa | Glycosidase inhibitors |
| US10556902B2 (en) | 2016-02-25 | 2020-02-11 | Asceneuron Sa | Glycosidase inhibitors |
| US11261183B2 (en) | 2016-02-25 | 2022-03-01 | Asceneuron Sa | Sulfoximine glycosidase inhibitors |
| WO2017218950A1 (en) | 2016-06-17 | 2017-12-21 | Forma Therapeutics, Inc. | 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors |
| WO2018165520A1 (en) | 2017-03-10 | 2018-09-13 | Vps-3, Inc. | Metalloenzyme inhibitor compounds |
| IT201700041723A1 (it) | 2017-04-14 | 2018-10-14 | Italfarmaco Spa | Nuovi inibitori selettivi di HDAC6 |
| WO2019037861A1 (en) * | 2017-08-24 | 2019-02-28 | Asceneuron S.A. | ANNOTATED GLYCOSIDASE INHIBITORS |
| EP3672959A1 (en) | 2017-08-24 | 2020-07-01 | Asceneuron SA | Linear glycosidase inhibitors |
| US11731972B2 (en) | 2018-08-22 | 2023-08-22 | Asceneuron Sa | Spiro compounds as glycosidase inhibitors |
| CN113166083A (zh) | 2018-08-22 | 2021-07-23 | 阿森纽荣股份公司 | 用作糖苷酶抑制剂的哌嗪衍生物的琥珀酸盐和富马酸盐酸加成盐 |
| US12016852B2 (en) | 2018-08-22 | 2024-06-25 | Asceneuron Sa | Pyrrolidine glycosidase inhibitors |
| WO2020039028A1 (en) | 2018-08-22 | 2020-02-27 | Asceneuron S. A. | Tetrahydro-benzoazepine glycosidase inhibitors |
| ES2939730T3 (es) | 2019-01-17 | 2023-04-26 | Univ Lille | Compuestos de heteroarilo de 5 miembros que contienen un resto hidroxamato y su uso |
| CN114727974A (zh) * | 2019-07-30 | 2022-07-08 | 艾科尼佐治疗股份有限公司 | Hdac6抑制剂及其用途 |
| BR112022011917A2 (pt) | 2019-12-20 | 2022-09-06 | Tenaya Therapeutics Inc | Fluoroalquil-oxadiazois e seus usos |
| EP4326263A1 (en) | 2021-04-23 | 2024-02-28 | Tenaya Therapeutics, Inc. | Hdac6 inhibitors for use in the treatment of dilated cardiomyopathy |
| MX2023012875A (es) | 2021-05-04 | 2024-01-12 | Tenaya Therapeutics Inc | Inhibidores 2-fluoro alquil-l,3,4-oxadiazol-5-il-tiazol de hdac6 para su uso en el tratamiento de enfermedades metabólicas y hfpef. |
| WO2025215092A1 (en) | 2024-04-10 | 2025-10-16 | Institut National de la Santé et de la Recherche Médicale | Selective hdac6 inhibitors for use in the treatment of myotonic dystrophy type 1 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6232320B1 (en) * | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
| CN1332743A (zh) | 1998-06-04 | 2002-01-23 | 艾博特公司 | 抑制细胞粘附抗炎化合物 |
| HK1045306A1 (zh) | 1999-06-03 | 2002-11-22 | Abbott Laboratories | 抑制细胞黏附的抗炎化合物 |
| WO2001038322A1 (en) * | 1999-11-23 | 2001-05-31 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| CA2426942C (en) | 2000-10-31 | 2014-06-03 | Mark P. Wentland | 8-carboxamido-2,6-methano-3-benzazocines |
| US20040091951A1 (en) * | 2002-02-07 | 2004-05-13 | Axys Pharmaceuticals, Inc. | Assay for measuring acetylation or deacetylation activity of an enzyme |
| EP1485348B1 (en) * | 2002-03-13 | 2008-06-11 | Janssen Pharmaceutica N.V. | Carbonylamino-derivatives as novel inhibitors of histone deacetylase |
| US7250514B1 (en) * | 2002-10-21 | 2007-07-31 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| EP1608628A2 (en) | 2003-03-17 | 2005-12-28 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| US7935724B2 (en) * | 2003-10-09 | 2011-05-03 | Merck Hdac Research, Llc | Thiophene and benzothiophene hydroxamic acid derivatives |
| TW201245229A (en) | 2003-10-14 | 2012-11-16 | Hoffmann La Roche | Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication |
| EP1682538A4 (en) * | 2003-10-27 | 2009-05-27 | S Bio Pte Ltd | BIARYL-ASSOCIATED HYDROXAMATE: PREPARATION AND PHARMACEUTICAL APPLICATIONS |
| WO2005108367A1 (en) * | 2004-05-03 | 2005-11-17 | Envivo Pharmaceuticals, Inc. | Compounds for treatment of neurodegenerative diseases |
| WO2007115408A1 (en) | 2006-04-10 | 2007-10-18 | Painceptor Pharma Corporation | Compositions and methods for modulating gated ion channels |
| GB0620259D0 (en) | 2006-10-12 | 2006-11-22 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| CA2671550A1 (en) * | 2006-12-15 | 2008-06-26 | Novartis Ag | Heterocycle compounds and methods of use thereof |
| US8440830B2 (en) | 2007-09-19 | 2013-05-14 | 4Sc Ag | Tetrahydro-fused pyridines as histone deacetylase inhibitors |
| EP2100879A1 (en) | 2008-03-13 | 2009-09-16 | 4Sc Ag | Novel N-substituted tetrahydroisoquinoline/isoindoline hydroxamic acid compounds |
| EP2265590B8 (en) | 2008-04-15 | 2016-07-27 | Pharmacyclics LLC | Selective inhibitors of histone deacetylase |
| US8624040B2 (en) * | 2009-06-22 | 2014-01-07 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
| EP2445340B1 (en) | 2009-06-22 | 2016-05-18 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
| WO2012027564A1 (en) | 2010-08-26 | 2012-03-01 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
| US8778931B2 (en) * | 2010-12-22 | 2014-07-15 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
-
2010
- 2010-06-21 EP EP10792446.6A patent/EP2445340B1/en active Active
- 2010-06-21 JP JP2012516072A patent/JP5798115B2/ja not_active Expired - Fee Related
- 2010-06-21 CA CA2765678A patent/CA2765678A1/en not_active Abandoned
- 2010-06-21 US US12/803,169 patent/US9096518B2/en not_active Expired - Fee Related
- 2010-06-21 WO PCT/US2010/001801 patent/WO2010151318A1/en not_active Ceased
-
2015
- 2015-01-26 JP JP2015012045A patent/JP2015078237A/ja active Pending
- 2015-07-07 US US14/792,762 patent/US9321731B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012530703A5 (enExample) | ||
| TWI332943B (en) | Taxol enhancer compounds | |
| JP4167173B2 (ja) | 抗腫瘍剤としての使用のためのベンゾイルスルホンアミドおよびスルホンベンズアミジン | |
| KR101942151B1 (ko) | Hbv 감염에 대한 항바이러스 물질 | |
| JP2009507909A5 (enExample) | ||
| JPH09511764A (ja) | 新規ピペラジン誘導体、その製造方法及びそれを含有する組成物 | |
| JP2005505506A5 (enExample) | ||
| JP2018535963A5 (enExample) | ||
| AU2018260314A1 (en) | Antitumoral compounds | |
| JP2011051993A5 (enExample) | ||
| JP6851989B2 (ja) | 医薬用共結晶及びその用途 | |
| RU2012153164A (ru) | Производные мочевины и их терапевтическое применение при лечении, среди прочего, заболеваний дыхательного пути | |
| CN108699046A (zh) | 用ezh2抑制剂治疗成神经管细胞瘤的方法 | |
| CN107382966B (zh) | 一类荜茇酰胺-川芎嗪杂合物、制备方法及医药用途 | |
| JP2018520147A (ja) | 医薬共結晶組成物及びその用途 | |
| JP2025513554A (ja) | Ｈｐｋ１キナーゼ阻害剤のヒトの病原体感染の予防及び／又は治療への応用 | |
| JP6314129B2 (ja) | グアニジノ安息香酸エステル化合物 | |
| JP6262363B2 (ja) | ブロモドメイン阻害剤としてのキノリン誘導体 | |
| CN111825611A (zh) | 4(1h)-奎诺酮衍生物及其用途 | |
| CN113260616A (zh) | 用于治疗呼吸系统疾病的新型化合物 | |
| JP7229482B2 (ja) | 新規アミド系化合物、並びにそれを用いたＰｉｎ１阻害剤、炎症性疾患の治療剤及び癌の治療剤 | |
| JP6952911B2 (ja) | ２−（αヒドロキシペンチル）安息香酸の有機アミンエステル誘導体薬物 | |
| HUE027375T2 (en) | Phenyl guanidine derivatives | |
| JPH0372455A (ja) | レトロウィルス感染症用薬剤 | |
| JP2019518029A5 (enExample) |